lURIE CANCER CENTER AND Northwestern Medicine
EXPERTS TO PRESENT AT ASCO 2023
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss leading-edge research in cancer care at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 at McCormick Place in Chicago, and Online. Visit us at Booth 3026.
The program features more than 200 sessions complementing the meeting’s theme: Partnering with Patients - The Cornerstone of Cancer Care and Research.
During ASCO’s Plenary Session, Rimas V. Lukas, MD, will discuss a practice-changing neuro-oncology study (Discussion of LBA1) and share implications for future research. Presentations in this special session on Sunday, June 4, showcase scientific research deemed to have the greatest impact on oncology research and treatment. Visit us at Booth 3026.
The program features more than 200 sessions complementing the meeting’s theme: Partnering with Patients - The Cornerstone of Cancer Care and Research.
During ASCO’s Plenary Session, Rimas V. Lukas, MD, will discuss a practice-changing neuro-oncology study (Discussion of LBA1) and share implications for future research. Presentations in this special session on Sunday, June 4, showcase scientific research deemed to have the greatest impact on oncology research and treatment. Visit us at Booth 3026.
Use #ASCO23 to follow and share insights from the meeting on Twitter, tagging:
- Lurie Cancer Center: @LurieCancer
- Northwestern Medicine: @NorthwesternMed
Lurie Cancer Center investigators who are leading sessions and presenting pivotal research findings, include*:
|
Date & Time
|
Session
|
Presenter
*Discussant
|
Learn More
|
|
Saturday, June 3
|
8:00 AM
|
Genitourinary Cancer – Kidney and Bladder
Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial. Abstract: 4527 |
|
|
|
Case-Based Panel
Optimizing Brain Metastases Treatments to Minimize and Manage Neurologic Toxicities The Radiation Oncologist Perspective |
|
|
|
|
|
Developmental Therapeutics – Immunotherapy
Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists. Abstract: 2583 |
|
|
|
Genitourinary Cancer—Prostate, Testicular, and Penile
Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA). Abstract: 5026 |
|
1:15 PM
|
Health Services Research and Quality Improvement
Disparities in intensity of care at the end-of-life for patients with gastrointestinal cancer. Abstract: 6658 Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma. Abstract: 6624
|
|
|
|
Prevention, Risk Reduction, and Hereditary Cancer
Metformin for chemoprevention of lung cancer in high-risk overweight or obese individuals. Abstract: TPS10636 |
|
|
|
Central Nervous System Tumors
Vulnerability to immune therapy in BRAF- and MYB-altered pediatric gliomas. Abstract: 2066 |
|
|
|
4:30 PM
|
Sarcoma
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27). Abstract: 11516 |
|
Sunday,
June 4 |
8:00 AM
|
Breast Cancer Metastatic
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC). Abstract: 1038 |
|
|
|
Genitourinary Cancer – Prostate, Testicular, and Penile
DDR and PARP Inhibition: What's the Damage? Abstract Discussion 2 |
|
|
|
11:30 AM
|
Breast Cancer Metastatic
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort. Abstract: 1021 |
|
|
|
1:00 PM
|
Plenary Session – Special Sessions
Abstract presentations in this session showcase scientific research deemed to have the highest merit and greatest impact on oncology research and practice. Experts in the field serve as discussants placing clinical research findings into perspective and sharing implications for future research. Discussion of LBA1, a practice-changing study of the novel brain-penetrant IDH1 inhibitor (vorasidenib) for the treatment of IDH-mutated glioma, a primary brain tumor that often affects young patients in the third or fourth decade of life. |
|
|
|
4:30 PM
|
Breast Cancer – Local/Regional/Adjuvant
Breast Cancer Surgery: Too Much, Too Little, Just Right Abstract Discussion 4 |
|
Monday, June 5
|
8:00 AM
|
Hematologic Malignancies – Lymphoma & Chronic Lymphocytic Lymphoma
Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma. Abstract: 7564 |
|
|
|
Gastrointestinal Cancer – Gastroesophageal, Pancreatic and Hepatobiliary
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. Abstract: TPS4204 |
|
|
|
4:30 PM
|
Gynecologic Cancer
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers. Abstract: 5517 |
|
Tuesday, June 6
|
12:45 PM
|
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Lymphoma
Striking a Balance with Immunotherapy in Non-Hodgkin Lymphoma. Abstract Discussion 3 |
Publication Only
|
Head and Neck Cancer
|
Retrospective analysis of NUT carcinoma: The Northwestern experience. Abstract e18096
|
First Author: Anthony Serritella, MD
|
NORTHWESTERN MEDICINE onCOLOGY
|
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a global leader in a broad range of cancer types thanks to its dedication to comprehensive research, world-renowned faculty and staff and its commitment to making ongoing advances in medical, surgical, radiation and interventional oncology. The Lurie Cancer Center is designated by the National Cancer Institute as one of only 53 comprehensive cancer centers in the nation recognized for their scientific leadership, resources and the depth and breadth of their research. In addition, Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN) and our physicians actively participate in writing NCCN patient guidelines for each type cancer.
|